A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)
Publisher: John Wiley & Sons Inc
E-ISSN: 1097-0142|121|20|3639-3648
ISSN: 0008-543x
Source: CANCER, Vol.121, Iss.20, 2015-10, pp. : 3639-3648
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract